Compare DLPN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | MBRX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 12.7M |
| IPO Year | 2008 | 2016 |
| Metric | DLPN | MBRX |
|---|---|---|
| Price | $1.13 | $0.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 6.3K | ★ 585.0K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.87 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $56,699,389.00 | N/A |
| Revenue This Year | $14.73 | N/A |
| Revenue Next Year | $7.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $1.02 | $0.16 |
| 52 Week High | $1.88 | $7.98 |
| Indicator | DLPN | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 33.99 |
| Support Level | $1.06 | $0.16 |
| Resistance Level | $1.20 | $0.67 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 29.37 | 9.21 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing, and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials. The company operates within the U.S.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.